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Body of Letter:
National data show an increasing trend of reduced azithromycin susceptibility (AZM-RS) 
among Neisseria gonorrhoeae (Ng) isolates, especially in the Midwest.1 Sentinel 
surveillance data from the Gonococcal Isolate Surveillance Project, which examines isolates 
from men with urethritis from 27 sites across the United States, indicates that the proportion 
of AZM-RS Ng isolates (minimum inhibitory concentration [MIC] ≥2 μg/mL) increased 4-
fold between 2013 (0.6%) and 2014 (2.5%).1 Most AZM-RS Ng infections occur in men 
who have sex with men.1,2
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The Columbus Public Health STD clinic in Columbus, Ohio, has participated in the 
Gonococcal Isolate Surveillance Project since 2012. We detected zero cases of AZM-RS Ng 
in 2015 and 5 cases in 2016 (April, June, July, August, and December). However, we 
identified 30 cases between January and July 2017; 25 isolates had an AZM MIC of 2 
μg/mL and 5 had an MIC of 8 μg/mL. To improve local detection of AZM-RS Ng, we 
compared characteristics of men with AZM-susceptible Ng urethritis (n = 224) and those 
with AZM-RS Ng urethritis (n = 30) detected between January and July 2017 (Table 1). 
Most men with AZM-RS Ng urethritis were identified in the months of June (n = 8) and July 
2017 (n = 10), suggesting an accelerating trend. Compared with men with AZM-susceptible 
Ng urethritis, men with AZM-RS Ng urethritis were more likely to be white (P = 0.02), to 
report intravenous drug use in the previous year (P = 0.008), and to be HIV-positive (P = 
0.04). Although more than half (53%) of men with AZM-RS Ng were heterosexual, the 
proportion identifying as homosexual (47%) was much higher than the proportion of AZM-
susceptible men identifying as homosexual (17%; P = 0.003). We observed no significant 
differences by age, lifetime or recent Ng history, symptoms, recent international travel, 
recent sex work exposure, recent non–injection drug use, or recent antibiotic use. Although 
there was one Ng isolate with an increased MIC value to cefixime (MIC, 0.250 μg/mL) and 
one to both cefixime (MIC, 0.250 μg/mL) and ceftriaxone (MIC, 0.125 μg/mL), neither of 
these had concomitant reduced susceptibility to AZM. Ninety-seven percent (n = 29) of men 
with AZM-RS Ng urethritis received single-dose ceftriaxone (250 mg) plus AZM (1 g), and 
3% (n = 1) received single-dose ceftriaxone (250 mg) plus 7 days of doxycycline (100 mg 
twice per day).
We report a rapid and alarming increase in cases of AZM-RS Ng urethritis in 2017 in 
Columbus, Ohio (12% of Ng isolates examined). In contrast to recent reports from King 
County, WA,2 more than half of our AZM-RS Ng infections occurred in heterosexual 
patients. The Centers for Disease Control and Prevention recommends dual therapy 
(ceftriaxone plus AZM) to treat Ng3; the importance of this approach is confirmed by our 
data, because none of our AZM-RS Ng isolates showed increased MICs to ceftriaxone. 
However, a genetically linked cluster of 8 Ng isolates with high-level AZM resistance by 
agar dilution (MIC, >16 μg/mL) was reported in Hawaii. Five of these isolates had 
simultaneous increased MICs to ceftriaxone (MIC, 0.125 μg/mL),4 further heightening 
public health concerns about the lack of alternative effective antibiotic options for the 
treatment of Ng. Expanded surveillance, rapid resistance testing, and new antibiotics are 
urgently needed in the face of rising Ng antibiotic resistance.
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